Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Phase 3TerminatedNCT00302770

AstraZeneca50 enrolled

Overview

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Social Anxiety Disorder

Interventions

quetiapineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written Confirmed Consent, * All patients meet the DSM IV criteria for generalized social anxiety disorder, * A score ≥ 60 on the LSAS, * male and female aged between 18 and 65 years Exclusion Criteria: * Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV, * alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months, * any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder, * patients at risk of suicide

Locations (1)

Research Site

Utrecht, Netherlands

Outcomes

Primary Outcomes

Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint

Secondary Outcomes

Number of responders, time to onset of response of sustained response to treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.